FDA Grants Priority Review to Tisotumab Vedotin for Recurrent/Metastatic Cervical CancerApril 12th 2021
Based on results of the phase 2 innovaTV 204 trial, the FDA granted priority review to tisotumab vedotin as a potential therapy for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Eribulin May Hold Promise in Advanced/Recurrent Cervical Cancer Not Previously Treated With PaclitaxelMarch 21st 2021
Although responses were limited in patients with paclitaxel-pretreated cervical cancer, eribulin may still show promise in those who are naïve to treatment with the chemotherapy agent.
Cemiplimab Impresses in a Phase 3 Trial of Cervical Cancer, Regulatory Submission ExpectedMarch 15th 2021
Promising overall survival results lead to an early stop to a phase 3 trial of cemiplimab versus chemotherapy in relapsed/refractory cervical cancer, according to the drug’s developer.
Adjuvant Sequential RT More Effective Than Concurrent RT or RT Alone for Patients with Cervical Cancer Following HysterectomyFebruary 19th 2021
These phase 3 study results support the use of sequential chemoradiation as a preferred adjuvant treatment following radical hysterectomy for patients with early-stage cervical cancer.
Biologics License Application for Tisotumab Vedotin to Treat Patients With Cervical Cancer Is Submitted to FDAFebruary 11th 2021
Seagen and Genmab hope to receive accelerated approval from the FDA for tisotumab vedotin monotherapy as treatment for patients with cervical cancer in the recurrent or metastatic setting.
New Guidance for Testing of Minimal Abnormalities Detected in Cervical Cancer ScreeningOctober 18th 2020
Following the new ASCCP-led national consensus guidelines for managing abnormal cervical cancer screening tests, these new guidelines estimate risk based on an individual’s risk factors, thus allowing for more personalized care management.
Balstilimab Monotherapy, Combination Shows Promise in Recurrent/Metastatic Cervical CancerSeptember 25th 2020
Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.
Study Sees Encouraging Responses with Tisotumab Vedotin in Recurrent/Metastatic Cervical CancerSeptember 24th 2020
“Results from this study suggest that tisotumab vedotin has the potential to be a new therapy for patients with previously treated recurrent and/or metastatic cervical cancer,” said lead study author Robert L. Coleman, MD, FACOG, FACS.
Early Posttherapy Clearance of HPV May Be Associated with Improved Survival for Cervical CancerSeptember 3rd 2020
Researchers suggested that this 6-week window may represent a critical time point at which decisions could be made regarding treatment escalation for this patient population.
Julie Torode Discusses the WHO Cervical Cancer Elimination StrategyAugust 24th 2020
The director of special projects at the Union for International Cancer Control spoke about the strategy released by the World Health Organization and what needs to occur to achieve the goals laid out by the organization.
Tisotumab Vedotin Sees Positive Topline Results in the Phase 2 InnovaTV 204 TrialJune 30th 2020
The trial is evaluating tisotumab vedotin administered every 3 weeks for the treatment of patients who have relapsed or progressed on or after prior treatment for recurrent or metastatic cervical cancer.
Using Any HPV Vaccination May Reduce Burden of DiseaseFebruary 12th 2020
Researchers suggested that the receipt of 1, 2, or 3 doses of an HPV vaccine by females aged 15 to 19 years was associated with a lower incidence of preinvasive cervical disease when compared to unvaccinated females.
HPV Vaccine Not Linked to Serious Complications in Adult WomenOctober 22nd 2017
A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
USPSTF Proposes New Guidelines for Cervical Cancer ScreeningOctober 11th 2017
The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.
FDA Approves First Biosimilar for Cancer TreatmentSeptember 18th 2017
The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.